Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
192.55B
Market cap192.55B
Price-Earnings ratio
10.33
Price-Earnings ratio10.33
Dividend yield
2.79%
Dividend yield2.79%
Average volume
11.76M
Average volume11.76M
High today
$43.97
High today$43.97
Low today
$42.25
Low today$42.25
Open price
$43.50
Open price$43.50
Volume
17.13M
Volume17.13M
52 Week high
$81.44
52 Week high$81.44
52 Week low
$35.12
52 Week low$35.12

NVO News

Nasdaq 7h
Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down

Key Points VK2735 is being developed in both subcutaneous and oral forms, and upcoming Phase 1 maintenance trial results are a major catalyst. VK2735 may offe...

Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down
The Motley Fool 1d
Lexicon Q1 2026 Earnings Transcript

Image source: The Motley Fool. Thursday, May 7, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer and Director — Dr. Mike Exton Senior Vice Presid...

Lexicon Q1 2026 Earnings Transcript
TipRanks 1d
Novo Nordisk Details Progress of 2026 Share Buyback Programme

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

Analyst ratings

54%

of 37 ratings
Buy
37.8%
Hold
54.1%
Sell
8.1%

More NVO News

Nasdaq 2d
Is Eli Lilly Starting an Nvidia-Style Run?

Key Points Eli Lilly recently won approval of a new product, strengthening its weight loss portfolio. The pharma giant has become the leader in the U.S. GLP-1...

Is Eli Lilly Starting an Nvidia-Style Run?
Simply Wall St 3d
Assessing Novo Nordisk Valuation After Mixed Returns And Earnings Snapshot

Advertisement Why Novo Nordisk (NYSE:NVO) Is Back On Investors’ Radar Novo Nordisk (NYSE:NVO) has drawn attention recently after its stock moved alongside rep...

Assessing Novo Nordisk Valuation After Mixed Returns And Earnings Snapshot
The Motley Fool 3d
Lilly's New Drug Just Delivered the Largest Weight Loss Ever Seen in a Clinical Trial -- Here's What It Means for Investors

The big news in the GLP-1 weight loss drug space right now is the introduction of pills. That seems to have broadened the appeal of GLP-1s, as many consumers si...

Lilly's New Drug Just Delivered the Largest Weight Loss Ever Seen in a Clinical Trial -- Here's What It Means for Investors
TipRanks 4d
Novo Nordisk’s CagriSema Trial Puts Next-Generation Obesity Strategy in Focus

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings...

MarketWatch 5d
Lilly’s GLP-1 medications will soon be covered by CVS, potentially opening access for millions of Americans

Eli Lilly’s stock is on track for a record close after the drugmaker disclosed that one of the nation’s most powerful pharmacy-benefit managers will start cover...

Lilly’s GLP-1 medications will soon be covered by CVS, potentially opening access for millions of Americans
Nasdaq 5d
Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now

Key Points Eli Lilly is performing very well as a business right now, which should please shareholders. Novo Nordisk has fallen behind Eli Lilly in the GLP-1...

Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now
Seeking Alpha 5d
France to become first EU nation to cover weight-loss meds

France has become the first EU nation to reimburse weight loss medications, including blockbuster GLP-1s from Novo Nordisk (NVO) and Eli Lilly (LLY), with cover...

France to become first EU nation to cover weight-loss meds

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.